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a b s t r a c t
Background: Long-term safety, particularly cardiovascular safety, is of special interest in maintenance
treatment of chronic obstructive pulmonary disease (COPD) with long-acting b2-agonists and long-acting
muscarinic antagonists, given potential cardiovascular effects.
Methods: Two 52-week Phase III trials (TONADO®) investigated tiotropium/olodaterol (5/5 and 2.5/5 mg)
versus tiotropium 2.5, 5 mg and olodaterol 5 mg. In a pre-speciﬁed safety analysis, investigator-reported
treatment-emergent adverse events (AEs), electrocardiogram and laboratory data were pooled. All
serious AE (SAE) reports were reviewed by an independent Adjudication Committee, which assessed
whether deaths, hospitalisations or intubations were respiratory, cardiovascular, cerebrovascular or other
disease related. Subgroup analyses investigated cardiovascular safety including major cardiac events in
patients with cardiovascular co-morbidities.
Results: This analysis comprised 3100 patients with moderate to very severe COPD, treated for 1 year,
including 784 patients with cardiovascular co-morbidities. AEs were balanced across treatments in the
total population as well as in patient subgroups with pre-existing cardiovascular co-morbidities. The
incidence and nature of events were consistent with the disease under study and a 1-year trial duration.
494/3100 patients contributed to an adjudicated analysis of SAEs: 260 had respiratory-related, 53 had
cardiovascular-related and 16 had cerebrovascular-related SAEs. Incidences of these SAEs were compa-
rable between treatments. There was no evidence of any increased risk for the combination compared to
the monotherapy groups.
Conclusions: These data provide conﬁdence for clinicians that tiotropium/olodaterol 5/5 mg can be safely
administered once-daily to patients with moderate to very severe COPD long-term, including those with
signiﬁcant cardiovascular co-morbidity.
Trial registry: ClinicalTrials.gov, Nos.: NCT01431274, NCT01431287.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Abbreviation list: AE, adverse event; COPD, chronic obstructive pulmonary disease; GOLD, Global initiative for chronic Obstructive Lung Disease; LABA, long-acting b2-
agonist; LAMA, long-acting muscarinic antagonist; MACE, major adverse cardiovascular event; MedDRA, Medical Dictionary for Regulatory Activities; SAE, serious adverse
event.
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1. Introduction
With the widespread use of long-acting muscarinic antagonists
(LAMAs) and long-acting b2-agonists (LABAs) in patients with
moderate to very severe chronic obstructive pulmonary disease
(COPD), it is important to evaluate their long-term safety, especially
when given in combination. Cardiovascular safety is of particular
interest, given the potential effects associated with both of these
drug classes [1e3]. Cardiovascular diseases are among the most
frequent serious co-morbid conditions in this patient population
[4e7] and patients with COPD are at substantially greater risk of
developing incident cardiac arrhythmia, thromboembolic disor-
ders, myocardial infarction and stroke compared to healthy in-
dividuals [8,9]. Recent evidence from clinical studies of the safety
and tolerability proﬁle of LABAs supports their long-term use in
COPD including those patients with a history, or increased risk, of
cardiovascular disease, when given alone or as a ﬁxed-dose com-
bination with an inhaled corticosteroid [10,11].
The efﬁcacy of tiotropium [12e19] and the novel LABA oloda-
terol [20e23] has been widely studied in patients with COPD. Two
large-scale, Phase III, 1-year studies (TONADO®) have shown su-
perior effects of tiotropium/olodaterol 5/5 mg on lung function and
health-related quality of life compared to either of its mono-
components [24]. Here we report on a comprehensive, pre-
speciﬁed safety assessment of tiotropium/olodaterol maintenance
treatment from this large population of patients with moderate to
very severe COPD, a substantial proportion of whom had cardio-
vascular co-morbidities at baseline.
2. Materials and methods
2.1. Study design
These were two replicate, randomised, double-blind, ﬁve-arm,
parallel-group, multicentre trials (TONADO®: Study 1237.5,
NCT01431274; Study 1237.6, NCT01431287) (Fig. 1). Patients were
randomised to tiotropium/olodaterol 2.5/5 mg or 5/5 mg, tiotropium
2.5 mg or 5 mg, or olodaterol 5 mg. All study drugs were delivered
once daily in the morning via two actuations of the blinded
Respimat® inhaler. This manuscript reports the data for the
worldwide approved dose of tiotropium/olodaterol 5/5 mg and its
monocomponents, tiotropium 5 mg and olodaterol 5 mg. Results for
all treatment groups are reported in Appendices 1e7.
The studies included patients aged 40 years with moderate to
very severe COPD (Global initiative for chronic Obstructive Lung
Disease [GOLD] 2e4). Further details can be found in Appendix 9.
The studies were conducted in accordance with the Declaration
of Helsinki, International Conference on Harmonisation Harmon-
ised Tripartite Guideline for Good Clinical Practice and local regu-
lations. Signed, informed consent was obtained from all patients.
Institutional Review Board approval is described in Appendix 9.
2.2. Evaluations and outcome measures
Full details of the primary efﬁcacy end points of these studies
have previously been described [24]. The present analysis focuses
on a pre-speciﬁed safety evaluation of pooled data from the two
studies to maximise the available safety data.
Treatment-emergent adverse events (AEs) were recorded
throughout the 52-week trial, regardless of causality. Vital signs
were recorded at screening, baseline and after 12, 24 and 52 weeks
of treatment, and measured before pre-dose pulmonary function
tests and the 60-min post-dose pulmonary function tests. Twelve-
lead electrocardiogram recordings were performed at screening
and study withdrawal. In addition, 12-lead electrocardiogram re-
cordings were performed pre-dose and 40 min post-dose at base-
line and weeks 12, 24 and 52. A follow-up visit was performed 21
days after the 52 weeks of study treatment during which AEs,
concomitant therapies and salbutamol use (rescue medication)
were reviewed and recorded. At selected sites, 24-h Holter moni-
toring was performed in a subset of patients (150 per treatment
group) before randomisation and after week 12.
2.3. Adjudicated safety evaluation
An independent external expert Adjudication Committee that
was blinded to treatment independently assessed all serious
adverse events (SAEs) to determine if any of the deaths, hospital-
isations or intubations were respiratory, cardiovascular, cerebro-
vascular or other disease related. When an SAE was adjudicated as
respiratory related, further determination was made to assess if it
was related to COPD or pneumonia. When an SAE was adjudicated
as cerebrovascular related, further determination was made to
assess if it was related to stroke or other cerebrovascular disease.
2.4. Analysis
2.4.1. Overall AEs
All randomised patients who received at least one dose of
treatment were included in the safety analysis set (treated set).
Frequencies of investigator-reported AEs (coded using the Medical
Dictionary for Regulatory Activities [MedDRA]) were analysed
descriptively. The analysis was based on treatment-emergent AEs
and included those AEs that occurred after the ﬁrst dose of trial
medication and within 21 days after the last dose of trial
medication.
2.4.2. Aggregated end points
Aggregated safety end points reﬂecting cardiovascular safety
(using Standardised MedDRA Queries and Boehringer Ingelheim-
deﬁned pharmacovigilance end points) as well as major adverse
cardiovascular events (MACE) were compared across all treatment
groups and in subgroups of patients with a history of cardiac dis-
ease including cardiac arrhythmia and ischaemic heart disease.
2.4.3. Adjudicated safety analysis
A composite end point was deﬁned as the incidence of death,
hospitalisation and intubation for respiratory-, cardiovascular-,
Fig. 1. Trial design. QD ¼ once daily; R ¼ randomisation. Reproduced with permission
of the European Respiratory Society©: European Respiratory Journal Apr 2015, 45 (4)
969e979; http://dx.doi.org/10.1183/09031936.00136014.
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cerebrovascular- or other disease-related events/causes. Incidences
of the composite end point and its individual components were
evaluated based on adjudicated SAEs.
For comparisons of tiotropium/olodaterol with the respective
monotherapy components, time to ﬁrst event (end point) analysis
was conducted using stratiﬁed Cox regression, with study as a
stratum and treatment as the only factor in the model. Hazard ra-
tios with corresponding 95% conﬁdence intervals were calculated
based on this model. For hospitalisations and intubations, this was
the time to onset of the event; for deaths, this was the time to
death.
2.4.4. Subgroup analyses
Frequencies of AEs were compared in the following pre-deﬁned
subgroups: sex, age, race, COPD disease severity, inhaled cortico-
steroid use at baseline, medical history of diabetes mellitus, any
cardiac history, cardiac arrhythmia and ischaemic heart disease at
baseline. The deﬁnitions of the cardiovascular history disease
subgroups at baseline can be found in Appendix 9.
3. Results
3.1. Patient population and treatment exposure
In the TONADO® studies, 6887 patients were screened and 5163
patients were randomised to treatment. In this analysis of the
marketed doses, 3100 patients received at least one dose of study
medication (Study 1237.5: 1577 patients; Study 1237.6: 1523 pa-
tients). Baseline demographics were similar across the treatment
groups (Table 1). Results on the additional doses of tiotropium and
olodaterol can be found in the Appendix. Most patients were male
(72.6%) and classiﬁed as GOLD 2/3 (87.9%); GOLD 2 categorised as
moderate COPD with 50%  FEV1 <80% predicted and GOLD 3
categorised as severe COPD with 30%  FEV1 <50% predicted. In
addition, 37.0%were current smokers. Overall, 86.7% of patients had
diagnosed co-morbidities at baseline: 666 (21.5%) had cardiac dis-
orders and 1520 (49.0%) had vascular disorders including hyper-
tension. Mean exposure to study medication was similar across
treatment groups, ranging from 326 to 340 days (Table 1).
3.1.1. Overall incidence of AEs
Incidences of AEs, SAEs, investigator-reported treatment-related
AEs and AEs leading to death are presented in Table 2. Incidence of
AEs was generally balanced across all treatment groups; most
events were mild tomoderate in severity and 6.6% were considered
treatment related by the investigator (most frequently, respiratory
[2.0%] and gastrointestinal [1.5%] disorders). Incidences of SAEs and
deaths were also similar across treatment groups.
The most frequently reported AEs were from the MedDRA Sys-
tem Organ Classes of “respiratory, thoracic and mediastinal disor-
ders” and “infections and infestations” (Fig. 2), with COPD and
nasopharyngitis being the most commonly reported. The incidence
of these most common events was similar across treatment groups.
3.1.2. Cardiovascular AEs
Cardiovascular AEs were generally balanced across treatment
groups (Table 3) and the frequencies of events for tiotropium/olo-
daterol were not statistically signiﬁcantly different to those for the
monotherapy components. Cardiac arrhythmias were reported in
129 patients (4.2%; range 3.9e4.5%) and ischaemic heart disease in
70 patients (2.3%; range 2.1e2.5%).
Incidence of MACE ranged from 1.8% in the tiotropium arm to
2.4% in the olodaterol arm (Table 4). The exposure-adjusted rate
ratios for tiotropium/olodaterol vs the monotherapies were 0.94
Table 1
Demographic and baseline patient characteristics and extent of exposure.
Olodaterol
5 mg(n ¼ 1038)
Tiotropium
5 mg(n ¼ 1033)
Tiotropium/olodaterol
5/5 mg(n ¼ 1029)
Male, n (%) 764 (73.6) 755 (73.1) 733 (71.2)
Mean (SD) age, years 64.2 (8.2) 63.9 (8.6) 63.8 (8.3)
Smoking status, n (%)
Ex-smoker 660 (63.6) 663 (64.2) 629 (61.1)
Current smoker 378 (36.4) 370 (35.8) 400 (38.9)
Co-morbidities,a n (%) 897 (86.4) 902 (87.3) 890 (86.5)
Cardiac history 281 (27.1) 247 (23.9) 256 (24.9)
Cardiac rhythm disorders 100 (9.6) 87 (8.4) 98 (9.5)
Ischaemic heart disease 149 (14.4) 124 (12.0) 120 (11.7)
Vascular disordersb 511 (49.2) 513 (49.7) 496 (48.2)
Diabetes mellitus 152 (14.6) 136 (13.2) 125 (12.1)
GOLD, n (%)
1 (80%) 0 (0.0) 1 (0.1) 0 (0.0)
2 (50e<80%) 532 (51.3) 517 (50.0) 502 (48.8)
3 (30e<50%) 378 (36.4) 387 (37.5) 408 (39.7)
4 (<30%) 128 (12.3) 128 (12.4) 119 (11.6)
Baseline pulmonary medication, n (%)
SAMA 134 (12.9) 131 (12.7) 125 (12.1)
LAMA 365 (35.2) 346 (33.5) 378 (36.7)
SABA 424 (40.8) 401 (38.8) 400 (38.9)
LABA 491 (47.3) 450 (43.6) 486 (47.2)
ICS 505 (48.7) 466 (45.1) 506 (49.2)
Xanthines 96 (9.2) 109 (10.6) 108 (10.5)
Baseline cardiovascular medication,c n (%) 620 (59.7) 596 (57.7) 581 (56.5)
b-blocker 102 (9.8) 109 (10.6) 110 (10.7)
Mean (SD) extent of exposure, days 326.3 (96.6) 331.8 (91.3) 340.0 (79.6)
GOLD ¼ Global initiative for chronic Obstructive Lung Disease; ICS ¼ inhaled corticosteroid; LABA ¼ long-acting b2-agonist; LAMA ¼ long-acting muscarinic antagonist;
SABA ¼ short-acting b2-agonist; SAMA ¼ short-acting muscarinic antagonist; SD ¼ standard deviation.
a Deﬁnitions of the cardiovascular disease subgroups at baseline can be found in Appendix 9.
b Most frequent vascular co-morbidities (>1%) were aortic aneurysm (1.1%), atherosclerosis (1.5%), hypertension (43.7%), peripheral arterial occlusive disease (1.1%), pe-
ripheral vascular disorder (1.5%) and varicose vein (2.1%).
c Anti-hypertensives, diuretics, anti-arrhythmics, nitrates, vasodilators, platelet aggregation inhibitors, anticoagulants, cardiac glycosides.
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(95% conﬁdence interval: 0.53, 1.64) for olodaterol and 1.24 (95%
conﬁdence interval: 0.68, 2.26) for tiotropium, indicating no
statistically signiﬁcant difference. The most common MACE end
points included myocardial infarction (29 patients, 0.9% overall;
Table 2
Summary of general safety: incidence of total AEs, investigator reported as treatment-related AEs, AEs leading to discontinuations, SAEs and deaths.
Olodaterol
5 mg
Tiotropium
5 mg
Tiotropium/
olodaterol
5/5 mg
Total patients, n 1038 1033 1029
All AEs, n (%) 795 (76.6) 757 (73.3) 761 (74.0)
Treatment-related AEs 69 (6.6) 63 (6.1) 73 (7.1)
Severe AEsa 162 (15.6) 145 (14.0) 157 (15.3)
AEs leading to
discontinuation
103 (9.9) 93 (9.0) 76 (7.4)
SAEs 181 (17.4) 172 (16.7) 169 (16.4)
Fatal 14 (1.3) 17 (1.6) 18 (1.7)
AE ¼ adverse event; SAE ¼ serious adverse event.
a Deﬁned as incapacitating or causing inability to work or perform usual activities.
Fig. 2. Most frequently reported adverse events (>3% in any treatment group) by Medical Dictionary for Regulatory Activities System Organ Classes. COPD ¼ chronic obstructive
pulmonary disease.
Table 3
Summary of cardiovascular safety: cardiovascular AEs grouped by MedDRA SMQs.
MedDRA SMQ Olodaterol
5 mg
Tiotropium
5 mg
Tiotropium/olodaterol
5/5 mg
Total patients, n 1038 1033 1029
Cardiac arrhythmias, n (%) 41 (3.9) 47 (4.5) 41 (4.0)
Torsades de pointes/QT prolongation,a n (%) 5 (0.5) 3 (0.3) 5 (0.5)
Ischaemic heart disease,
n (%)
26 (2.5) 22 (2.1) 22 (2.1)
Cardiac failure, n (%) 12 (1.2) 8 (0.8) 5 (0.5)
Cerebrovascular disorders, n (%) 11 (1.1) 9 (0.9) 8 (0.8)
Hypertension, n (%) 53 (5.1) 35 (3.4) 36 (3.5)
AE ¼ adverse event; MedDRA ¼ Medical Dictionary for Regulatory Activities; SMQ ¼ Standardised MedDRA Query.
a There was no occurrence of Torsades de Pointes arrhythmia; all cases were single QT prolongation reported as an AE in any of the repeated electrocardiogram
measurements.
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range 0.8e1.1%), stroke (24 patients, 0.8% overall; range 0.7e1.0%)
and fatal cardiac disorders (System Organ Class) (10 patients, 0.3%
overall; range 0.3e0.4%).
3.1.3. Respiratory AEs
Respiratory events are presented in Appendices 6 and 10;
MedDRA Preferred Terms searched in the end points are detailed in
Appendix 11. Overall, there were no substantial differences in the
incidence of respiratory AEs across treatment groups.
3.1.4. Adjudicated SAEs
A summary of the adjudicated SAEs is provided in Table 5. In
total, 494 out of 3100 patients (15.9%; range 15.6e16.5% by treat-
ment arm) had adjudicated events meeting the criteria of the
composite end point (hospitalisation, intubation or death). The
large majority of the adjudicated SAEs (470 patients; 15.2%) were
hospitalisations, while there were 16 (0.5%) patients with intuba-
tion and 49 (1.6%) with fatal SAEs.
Fig. 3 provides a summary of the hazard ratios with 95% conﬁ-
dence intervals from the analysis of time to adjudicated SAEs. All
hazard ratios were close to one and there were no statistically
signiﬁcant differences between treatments for the comparisons
examined.
3.2. Subgroup analyses in pre-existing disease risk groups
The frequency of AEs tended to be higher in women, in patients
with diabetes mellitus and in those using inhaled corticosteroids at
baseline, and also with older age and severity of COPD (Table 6).
However, across these patient subgroups, there were no notable
differences between the treatment groups in overall incidence of
AEs.
A total of 784 (25.3%) patients had cardiac history at baseline
(Appendix 3). In general, the incidence of patients with at least one
AE was slightly higher in this subgroup compared to patients
without cardiac history (79.5% vs 73.0%); however, across the
treatment groups, incidences of AEs were broadly similar. In the
subset of patients with cardiac history, incidence of MACEwas 2.7%,
4.5% and 3.6% in the tiotropium/olodaterol 5/5 mg, tiotropium 5 mg
and olodaterol 5 mg groups, respectively. Although the incidences of
AEs tended to be higher in the subgroups of patients with cardiac
history or diabetes mellitus at baseline, there were no differences
between treatment groups.
In particular, there were no relevant differences across treatment
groups in cardiovascular AEs (deﬁned by Standardised MedDRA
Queries) in patients with or without pre-existing ischaemic heart
disease or cardiac rhythm disorders at baseline (Tables 6 and 7).
3.3. Other safety parameters
No signiﬁcant abnormalities in vital signs or laboratory pa-
rameters were observed. In addition, there were no clinically
relevant changes in any electrocardiogram parameter and no dose-
or time-related trends in QT interval (QTcF or QTcB) change across
treatment groups. With the 24-h Holter monitoring conducted in a
subset of 506 (16.3%) patients, there were no clinically relevant
dose- or time-related trends or patterns observed in the magni-
tudes of mean changes in heart rate, supraventricular premature
Table 4
Summary of cardiovascular safety MACE end points.
Olodaterol
5 mg
Tiotropium
5 mg
Tiotropium/
olodaterol
5/5 mg
Total patients, n 1038 1033 1029
MACE, n (%) 25 (2.4) 19 (1.8) 24 (2.3)
Cardiac disorders e SOC (fatal) 4 (0.4) 3 (0.3) 3 (0.3)
Vascular disorders e SOC (fatal) 1 (0.1) 1 (0.1) 2 (0.2)
Myocardial infarction e SMQ
(any)
10 (1.0) 8 (0.8) 11 (1.1)
Stroke e PV (any) 10 (1.0) 7 (0.7) 7 (0.7)
Sudden death e PT 0 (0.0) 1 (0.1) 1 (0.1)
Cardiac death e PT 0 (0.0) 0 (0.0) 0 (0.0)
Sudden cardiac death e PT 0 (0.0) 0 (0.0) 0 (0.0)
MACE ¼ major adverse cardiovascular event; MedDRA ¼ Medical Dictionary for Regulatory Activities; PT ¼ Preferred Term; PV ¼ sponsor-deﬁned pharmacovigilance end
point; SOC ¼ System Organ Class; SMQ ¼ Standardised MedDRA Query.
Table 5
Summary of adjudicated SAEs composite analyses.
Olodaterol
5 mg
Tiotropium
5 mg
Tiotropium/olodaterol
5/5 mg
Total patients, n 1038 1033 1029
Any adjudicated SAEs, n (%) 171 (16.5) 162 (15.7) 161 (15.6)
Any respiratory-related SAEs, n (%) 85 (8.2) 84 (8.1) 91 (8.8)
Key respiratory-related SAEs 78 (7.5) 70 (6.8) 83 (8.1)
COPD-related SAEs 67 (6.5) 65 (6.3) 71 (6.9)
Pneumonia-related SAEs 15 (1.4) 9 (0.9) 18 (1.7)
Other respiratory-related SAEs 7 (0.7) 17 (1.6) 11 (1.1)
Cardiovascular-related SAEs, n (%) 15 (1.4) 19 (1.8) 19 (1.8)
Any cerebrovascular SAEs,
n (%)
6 (0.6) 5 (0.5) 5 (0.5)
Stroke-related SAEs 3 (0.3) 5 (0.5) 2 (0.2)
Other cerebrovascular-related SAEs 4 (0.4) 0 (0.0) 3 (0.3)
Non-respiratory, non-cardiovascular or non-cerebrovascular-related SAEs, n (%) 78 (7.5) 74 (7.2) 71 (6.9)
COPD ¼ chronic obstructive pulmonary disease; SAE ¼ serious adverse event.
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Fig. 3. Forest plot of HRs (95% CIs) from the analysis of the time to adjudicated SAEs: (A) tiotropium/olodaterol 5/5 mg vs olodaterol 5 mg; (B) tiotropium/olodaterol 5/5 mg vs
tiotropium 5 mg. CI ¼ conﬁdence interval; HR ¼ hazard ratio; SAE ¼ serious adverse event.
Table 6
Clinically relevant cardiovascular AEs in patients with pre-existing cardiac rhythm disorder at baseline.
Cardiac rhythm disorder at baseline
NO
Cardiac rhythm disorder at baseline
YES
MedDRA SMQ Olodaterol
5 mg
Tiotropium
5 mg
Tiotropium/olodaterol
5/5 mg
Olodaterol
5 mg
Tiotropium
5 mg
Tiotropium/olodaterol
5/5 mg
Total patients, n 938 946 931 100 87 98
Any AEs, n (%) 723 (77.1) 685 (72.4) 686 (73.7) 72 (72.0) 72 (82.8) 75 (76.5)
Tachyarrhythmias, n (%) 11 (1.2) 11 (1.2) 8 (0.9) 2 (2.0) 1 (1.1) 6 (6.1)
Supraventricular tachyarrhythmias (incl. atrial
ﬁbrillation/ﬂutter)
5 (0.5) 7 (0.7) 1 (0.1) 1 (1.0) 1 (1.1) 4 (4.1)
Ventricular tachyarrhythmias 5 (0.5) 2 (0.2) 4 (0.4) 1 (1.0) 0 (0.0) 2 (2.0)
Ischaemic heart disease, n (%) 23 (2.5) 18 (1.9) 21 (2.3) 3 (3.0) 4 (4.6) 1 (1.0)
Myocardial infarction 8 (0.9) 6 (0.6) 10 (1.1) 2 (2.0) 2 (2.3) 1 (1.0)
Other ischaemic heart disease (non-infarction) 16 (1.7) 14 (1.5) 12 (1.3) 3 (3.0) 2 (2.3) 0 (0.0)
Cardiac failure, n (%) 8 (0.9) 5 (0.5) 5 (0.5) 4 (4.0) 3 (3.4) 0 (0.0)
Cerebrovascular disorders, n (%) 10 (1.1) 9 (1.0) 8 (0.9) 1 (1.0) 0 (0.0) 0 (0.0)
Haemorrhagic 6 (0.6) 4 (0.4) 3 (0.3) 0 (0.0) 0 (0.0) 0 (0.0)
Ischaemic 6 (0.6) 7 (0.7) 7 (0.8) 1 (1.0) 0 (0.0) 0 (0.0)
Hypertension, n (%) 47 (5.0) 28 (3.0) 34 (3.7) 6 (6.0) 7 (8.0) 2 (2.0)
AE ¼ adverse event; MedDRA ¼ Medical Dictionary for Regulatory Activities; SMQ ¼ Standardised MedDRA Query.
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beat indices or ventricular premature beat indices.
4. Discussion
This predeﬁned pooled analysis of data from two large regis-
tration trials demonstrated that tiotropium/olodaterol 5/5 mg had
acceptable long-term safety and tolerability across a spectrum of
patients with moderate to very severe COPD.
Pooled long-term safety data for new therapies provide
comprehensive information to practising clinicians beyond what is
available from individual studies. With this in mind, the studies
included in our analysis were designed to provide long-term data
over 1 year from a large patient population representative of clin-
ical practice (including very severe COPD). In addition, the use of an
independent Adjudication Committee that was blinded to the
treatment arms provided robust validation and standardised
analysis of the SAEs, hence minimising variation between study
sites in how they are reported. The analysis was based on a large
pooled database, with a high proportion of patients having re-
ported pre-existing cardiac history (~25%) or vascular (~50%) co-
morbidities. This allowed the assessment of safety across a broad
range of patient subtypes including those with histories of car-
diovascular disease and diabetes mellitus, both of which are prev-
alent in patients with COPD.
The important ﬁnding from this safety analysis was that the AE
proﬁle of a combination LAMA/LABA was comparable to that of its
monocomponents, ie, there was no additive adverse safety effect by
combining the two different mechanisms of action. In particular,
the incidence of cardiovascular events was not different across the
treatment groups and there was a low incidence of cardiovascular
AEs in those patients with cardiovascular co-morbidities at base-
line. The incidence of respiratory-related AEs was also similar
across the treatment groups. A strength of the current analysis was
the data from a pre-planned adjudicated analysis of all SAEs
demonstrating that the risk of having an event (composite end
point of hospitalisations, intubations and death) was similar for
tiotropium/olodaterol 5/5 mg compared to the monotherapy com-
ponents (tiotropium 5 mg and olodaterol 5 mg). These results pro-
vide comprehensive and robust evidence for the acceptable long-
term safety of the tiotropium/olodaterol 5/5 mg dose and the
monocomponents with regards to cardiovascular and respiratory
safety. Incidences of AEs, SAEs and fatal AEs were shown to be
comparable between treatment groups with no unexpected safety
ﬁndings. In addition, there were no differences in the risk of MACE
or cardiac disorders System Organ Class across treatment groups in
the study population, including subgroups with pre-existing car-
diovascular disease. The numbers of ﬁrst severe exacerbation were
in the range (~6%) of reported SAEs for COPD and in line with our
published exacerbation analyses [25].
In the TONADO® studies, the 5/5 mg dose was shown to provide
beneﬁts across efﬁcacy end points, including patients' health status
(as determined by St George's Respiratory Questionnaire total
scores) [24]. This supports the favourable beneﬁt-risk proﬁle of the
5/5 mg dose of tiotropium/olodaterol.
In contrast to other LAMAs, tiotropium has been marketed for a
long time and consequently has the largest safety database avail-
able for any long-acting bronchodilator. A recent analysis of a very
large database of patients with COPD showed that tiotropium does
not increase the overall risks of AEs, SAEs, fatal AEs or cardiovas-
cular events compared to placebo [26]. Olodaterol has also been
compared to placebo: in four 1-year studies of once-daily oloda-
terol (5 or 10 mg), the AE proﬁle was similar to that of placebo [27].
Further support for the safety of LAMA/LABA combinations has
been provided in a pooled analysis of safety data from the clinical
programmes of indacaterol, glycopyrronium and indacaterol/gly-
copyrronium [28]. Although based on 14 studies with differing
designs and durations, this analysis also demonstrated no increased
risk with this combination compared to the monotherapy compo-
nents. The safety of umeclidinium/vilanterol was recently assessed
in a 52-week, placebo-controlled study [29]. While the incidence of
AEs was shown to be similar between placebo and umeclidinium/
vilanterol, no such comparison can be made from our studies
because it was considered unethical to allocate patients with severe
to very serve COPD to placebo alone over a 1-year period. However,
in a shorter-term, 12-week study of tiotropium/olodaterol, both
doses (2.5/5 and 5/5 mg) were well tolerated, with an overall inci-
dence of AEs similar to placebo [30]. In addition, data from a pooled
analysis from three 6-week crossover studies showed that the
incidence of AEs was similar with tiotropium/olodaterol, the
monocomponents and placebo (Appendix 12). Although the overall
incidence of AEs and SAEs was generally lower in the umeclidi-
nium/vilanterol study, the patient population had less severe COPD
(all GOLD 1e3) than in our analysis, which comprised >10% of pa-
tients with GOLD 4 disease. In addition, our analysis was based on a
longer follow-up period (21 days after discontinuation of study
treatment vs 1 day post-treatment in the umeclidinium/vilanterol
study) [31].
When interpreting these results, some additional factors should
Table 7
Clinically relevant cardiovascular AEs in patients with pre-existing ischaemic heart disease at baseline.
Ischaemic heart disease at baseline
NO
Ischaemic heart disease at baseline
YES
MedDRA SMQ Olodaterol
5 mg
Tiotropium
5 mg
Tiotropium/olodaterol
5/5 mg
Olodaterol
5 mg
Tiotropium
5 mg
Tiotropium/olodaterol
5/5 mg
Total patients, n 889 909 909 149 124 120
Any AEs, n (%) 680 (76.5) 656 (72.2) 668 (73.5) 115 (77.2) 101 (81.5) 93 (77.5)
Tachyarrhythmias, n (%) 12 (1.3) 10 (1.1) 9 (1.0) 1 (0.7) 2 (1.6) 5 (4.2)
Supraventricular tachyarrhythmias (incl. atrial
ﬁbrillation/ﬂutter)
6 (0.7) 7 (0.8) 4 (0.4) 0 (0.0) 1 (0.8) 1 (0.8)
Ventricular tachyarrhythmias 5 (0.6) 1 (0.1) 2 (0.2) 1 (0.7) 1 (0.8) 4 (3.3)
Ischaemic heart disease, n (%) 20 (2.2) 14 (1.5) 12 (1.3) 6 (4.0) 8 (6.5) 10 (8.3)
Myocardial infarction 8 (0.9) 6 (0.7) 9 (1.0) 2 (1.3) 2 (1.6) 2 (1.7)
Other ischaemic heart disease (non-infarction) 13 (1.5) 9 (1.0) 4 (0.4) 6 (4.0) 7 (5.6) 8 (6.7)
Cardiac failure, n (%) 5 (0.6) 4 (0.4) 5 (0.6) 7 (4.7) 4 (3.2) 0 (0.0)
Cerebrovascular disorders, n (%) 9 (1.0) 7 (0.8) 6 (0.7) 2 (1.3) 2 (1.6) 2 (1.7)
Haemorrhagic 5 (0.6) 3 (0.3) 2 (0.2) 1 (0.7) 1 (0.8) 1 (0.8)
Ischaemic 7 (0.8) 5 (0.6) 5 (0.6) 0 (0.0) 2 (1.6) 2 (1.7)
Hypertension, n (%) 44 (4.9) 32 (3.5) 32 (3.5) 9 (6.0) 3 (2.4) 4 (3.3)
AE ¼ adverse event; MedDRA ¼ Medical Dictionary for Regulatory Activities; SMQ ¼ Standardised MedDRA Query.
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be considered. The current analysis of a large database, with >1000
patients per treatment arm, adds to the evidence base with respect
to the safety of the Respimat® device. It should be noted that there
is no placebo group in this study as it was deemed inappropriate to
include patients with symptomatic COPD in a placebo arm, without
the use of any long-acting bronchodilator, in a study lasting 1 year
[24]. In line with standard practice, unstable patients, who were
unlikely to reach the end of the study period, were excluded from
this Phase III trial. Additionally, this study does not inform on the
safety of tiotropium/olodaterol in the small fraction of COPD pa-
tients with very severe recent or unstable pre-existing cardiac co-
morbidities. Overall, no imbalances in mortality were seen over 1
year and the nature and frequencies of fatal events were as ex-
pected given the study duration and COPD population under
investigation [13,32].
5. Conclusions
These data, taken together with those from the wider Phase III
clinical programme, provide evidence for the long-term safety and
tolerability of once-daily tiotropium/olodaterol 5/5 mg, as validated
by an independent external Adjudication Committee, in patients
with moderate to very severe COPD.
Importantly, there was no evidence of increased cardiovascular
risk with tiotropium/olodaterol 5/5 mg in comparison to its
monocomponents.
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